GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Preferred Dividends

ImmunityBio (FRA:26CA) Preferred Dividends : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. ImmunityBio's preferred dividends for the three months ended in Sep. 2024 was €0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

ImmunityBio Preferred Dividends Historical Data

The historical data trend for ImmunityBio's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Preferred Dividends Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Dividends
- - - - -

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ImmunityBio Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

ImmunityBio  (FRA:26CA) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Preferred Dividends
Comparable Companies
GERN LGND MIRM AKRO WVE TARS HRMY SLNO IRON AGIO VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IBRX:USA 26CA:Germany
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
Website
https://www.immunitybio.com
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

ImmunityBio Headlines

No Headlines